NCT03890289 2024-11-21GAUDEALISFondazione Italiana Linfomi - ETSPhase 2 Terminated5 enrolled 13 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT01620216 2021-11-04Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaOHSU Knight Cancer InstitutePhase 2 Terminated12 enrolled 12 charts
NCT03742323 2021-09-05REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic LeukemiaPETHEMA FoundationPhase 1/2 Terminated6 enrolled
NCT02928510 2021-07-14Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic LymphomaJonsson Comprehensive Cancer CenterTerminated1 enrolled
NCT02439138 2017-01-11Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström MacroglobulinemiaDana-Farber Cancer InstitutePhase 2 Terminated5 enrolled 8 charts